Cite
HARVARD Citation
Thieblemont, C. et al. (2023). Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. Journal of clinical oncology. 41 (12), pp. 2238-2247. [Online].